Dr. André-Guy Martin is a clinical radio-oncologist and brachytherapy specialist with the CHU de Québec radio-oncology Department. He is also a research associate at the Centre de recherche du CHU de Québec-Laval University, Oncology Axis, affiliated with the Laval University Cancer Research Center.
Having graduated with a PhD in radio-oncology from Laval University in 2002, he went on to train in brachytherapy and obtained a Fellowship in Brachytherapy from the Brigham and Women’s Hospital of the prestigious Harvard Medical School in Boston, Massachusetts, U.S.A. He also completed a master’s degree in experimental medicine (MSc) focusing on prostate brachytherapy through the I-125 implant. He has been practicing brachytherapy since, and is mainly interested in urological and digestive sites (brachytherapy of the esophagus and rectum).
His area of interest in research focuses mainly on imagery-guided, concentrated brachytherapy. Along with his team, he has added the new modalities of magnetic resonance imagery and is working on setting up an automated guidance system. Thanks to his previous training in pharmacology, he has developed new pharmacotherapeutic avenues (cytoreduction) to optimize the brachytherapy approach. He contributes to and locally directs the NRG protocols.
Very involved in his area of research, he is the co-editor of the Contemporary Journal of Brachytherapy. On the provincial level, he is treasurer for l’Association des radio-oncologues du Québec. Internationally, he also supports the Groupe Francophone de Radiothérapie en Urologie.
Hôtel-Dieu de Québec
11 Côte du Palais, Bureau 3342
Canada G1R 2J6
Data not available
The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.Journal Article
Radiother Oncol, 109 (2), pp. 204-10, 2013, ISSN: 0167-8140.
A more efficient, radiation-free alternative to systematic chest x-ray for the detection of embolized seeds to the lung.Journal Article
Int J Radiat Oncol Biol Phys, 78 (4), pp. 1052-6, 2010, ISSN: 0360-3016.
[Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].Journal Article
Cancer Radiother, 14 (3), pp. 183-8, 2010, ISSN: 1278-3218.
Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis.Journal Article
Int J Radiat Oncol Biol Phys, 77 (1), pp. 153-9, 2010, ISSN: 0360-3016.
An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.Journal Article
Int J Radiat Oncol Biol Phys, 73 (3), pp. 679-84, 2009, ISSN: 0360-3016.
[The impact of 3D image guided prostate brachytherapy on therapeutic ratio: the Quebec University Hospital experience]Journal Article
Cancer Radiother, 11 (8), pp. 452-60, 2007, ISSN: 1278-3218.
Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard.Journal Article
Int J Radiat Oncol Biol Phys, 68 (4), pp. 1190-8, 2007, ISSN: 0360-3016.
Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.Journal Article
Int J Radiat Oncol Biol Phys, 67 (2), pp. 334-41, 2007, ISSN: 0360-3016.
Bypassing the learning curve in permanent seed implants using state-of-the-art technology.Journal Article
Int J Radiat Oncol Biol Phys, 67 (1), pp. 71-7, 2007, ISSN: 0360-3016.
Dosimetric consequences of manual pullback procedure for coronary artery radiotherapy with 90Sr/90Y beta-source.Journal Article
Brachytherapy, 3 (4), pp. 215-21, 2004, ISSN: 1538-4721.